Novo Nordisk A/S announced a forecast for 2026 with expected adjusted sales growth of -5% to -13% and operating profit growth of -5% to -13%, mainly impacted by regulatory changes and competition in the US. The company reported a 10% sales increase and a 6% operating profit increase for 2025, exceeding previous guidance.